Jardiance Launched for Type 2 Diabetes
Boehringer Ingelheim and Eli Lilly announced that Jardiance (empagliflozin) tablets are now available in pharmacies. Jardiance was approved on August 1, 2014 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Jardiance is a sodium glucose co-transporter-2 (SGLT2) inhibitor. It works by blocking the reabsorption of glucose in the kidney, increasing glucose excretion and lowering blood glucose levels in adults with type 2 diabetes.
Jardiance is available in 10mg and 25mg tablets in 30- and 90-count bottles.
For more information cal (800) 243-0127 or visit Jardiance.com.